Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials

scientific article

Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials is …
instance of (P31):
scholarly articleQ13442814
meta-analysisQ815382

External links are
P356DOI10.1016/J.OPHTHA.2012.11.042
P698PubMed publication ID23453513

P2093author name stringHoward Shapiro
David V Weinberg
Jason S Ehrlich
P433issue6
P921main subjectphase III clinical trialQ42824827
data analysisQ1988917
P304page(s)1278-1282
P577publication date2013-02-28
P1433published inOphthalmologyQ7098109
P1476titleRanibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials
P478volume120

Reverse relations

cites work (P2860)
Q24194251Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Q92133213Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Q35806580Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results
Q33900514Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: Retrospective comparative Analysis of an interventional case series.
Q34610139Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain
Q55312597Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.

Search more.